Cyclic Biphalin Analogues Incorporating a Xylene Bridge: Synthesis, Characterization, and Biological Profile.

In this work we enhanced the ring lipophilicity of biphalin introducing a xylene moiety, thus obtaining three cyclic regioisomers. Novel compounds have similar in vitro activity as the parent compound, but one of these (6a) shows a remarkable increase of in vivo antinociceptive effect. Nociception tests have disclosed its significant high potency and the more prolonged effect in eliciting analgesia, higher than that of biphalin and of the disulfide-bridge-containing analogue (7).

[1]  E. Novellino,et al.  Opioid Receptor Activity and Analgesic Potency of DPDPE Peptide Analogues Containing a Xylene Bridge. , 2017, ACS medicinal chemistry letters.

[2]  S. Cowell,et al.  Biphalin: The Foundation of Bivalent Ligands. , 2016, Current medicinal chemistry.

[3]  A. Lipkowski,et al.  Biphalin analogs containing β3-homo-amino acids at the 4,4′ positions: Synthesis and opioid activity profiles , 2015, Peptides.

[4]  E. Novellino,et al.  Novel cyclic biphalin analogue with improved antinociceptive properties. , 2014, ACS medicinal chemistry letters.

[5]  L. Devi,et al.  Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR Review 10 , 2014, British journal of pharmacology.

[6]  A. Lipkowski,et al.  The Biological Consequences of Replacing d‐Ala in Biphalin with Amphiphilic α‐Alkylserines , 2014, Chemical biology & drug design.

[7]  I. Wilhelm,et al.  Role of the blood-brain barrier in differential response to opioid peptides and morphine in mouse lines divergently bred for high and low swim stress-induced analgesia. , 2014, Acta neurobiologiae experimentalis.

[8]  V. Hruby,et al.  Biological active analogues of the opioid peptide biphalin: mixed α/β(3)-peptides. , 2013, Journal of medicinal chemistry.

[9]  J. Cornish,et al.  Synthesis and evaluation of disulfide bond mimetics of amylin-(1-8) as agents to treat osteoporosis. , 2012, Bioorganic & medicinal chemistry.

[10]  J. V. van Maarseveen,et al.  Synthesis of water-soluble scaffolds for peptide cyclization, labeling, and ligation. , 2012, Organic letters.

[11]  C. Hwang,et al.  A molecular dynamics study on opioid activities of biphalin molecule , 2011, Journal of molecular modeling.

[12]  James R. Baker,et al.  Protein Modification, Bioconjugation, and Disulfide Bridging Using Bromomaleimides , 2010, Journal of the American Chemical Society.

[13]  V. Hruby,et al.  Synthesis and biological activity of the first cyclic biphalin analogues. , 2006, Bioorganic & medicinal chemistry letters.

[14]  E. Novellino,et al.  Morphiceptin analogues containing a dipeptide mimetic structure: an investigation on the bioactive topology at the mu-receptor. , 2005, Journal of medicinal chemistry.

[15]  H. Loh,et al.  Heterodimerization of μ- and δ-Opioid Receptors Occurs at the Cell Surface Only and Requires Receptor-G Protein Interactions* , 2005, Journal of Biological Chemistry.

[16]  J. Marchand,et al.  Spinal antinociceptive effects of AA501, a novel chimeric peptide with opioid receptor agonist and tachykinin receptor antagonist moieties. , 2004, European journal of pharmacology.

[17]  A. Beaudet,et al.  Prolonged Morphine Treatment Targets δ Opioid Receptors to Neuronal Plasma Membranes and Enhances δ-Mediated Antinociception , 2001, The Journal of Neuroscience.

[18]  A. Lipkowski,et al.  The opioid peptide analogue biphalin induces less physical dependence than morphine. , 2001, Life sciences.

[19]  V. Hruby,et al.  A three-dimensional model of the delta-opioid pharmacophore: comparative molecular modeling of peptide and nonpeptide ligands. , 2000, Biopolymers.

[20]  T. Yamazaki,et al.  A topochemical approach to explain morphiceptin bioactivity. , 1993, Journal of medicinal chemistry.